Zhao Houyu, Zhang Tingting, Wang Yan, Fang Yiqun
Department of Diving Medicine, Navy Special Medical Center, Naval Medical University, Shanghai 200050, China.
Department of Underwater and Hyperbaric Medicine, Navy Special Medical Center, Naval Medical University, Shanghai 200050, China.
Int J Med Sci. 2025 Apr 13;22(9):2174-2185. doi: 10.7150/ijms.109842. eCollection 2025.
Blunt Liver Injury (BLI) is a common form of blunt abdominal trauma, with most cases managed non-surgically in current clinical practice. However, the absence of targeted treatments addressing the pathological changes associated with liver injury can result in prolonged recovery and potential long-term complications. Hyperbaric oxygen therapy (HBOT), known for its anti-inflammatory and antioxidant effects, has shown therapeutic potential in various diseases. This prospective randomized controlled experimental animal trial aimed to evaluate the effect of HBOT on BLI in a rat model. We established a BLI rat model by employing a free-fall weight method. Following injury, one group received no intervention, while the other was treated with HBOT (2.5 ATA, 60 minutes per session, once daily). Liver tissue and serum samples were collected at multiple time points for histological evaluation (HE staining), apoptosis detection (TUNEL staining), proliferation assessment (Ki67 immunohistochemical staining), and measurements of liver transaminase (ALT, AST), inflammatory markers (IL-1β, IL-6, TNF-α), and oxidative stress indicators (SOD, MDA, GSH). The results indicated that HBOT significantly reduced liver transaminase elevation, pathological damage, and hepatocyte apoptosis while promoting hepatocyte proliferation and accelerating liver function recovery. Mechanistically, HBOT alleviated oxidative stress and inflammatory response, highlighting its therapeutic potential. These findings provide further evidence supporting the application of HBOT in the clinical management of BLI. This study helps advance the clinical approach to BLI by shifting the focus from symptom management to mechanism-based treatment.
钝性肝损伤(BLI)是钝性腹部创伤的一种常见形式,在当前临床实践中,大多数病例采用非手术治疗。然而,缺乏针对肝损伤相关病理变化的靶向治疗可能导致恢复时间延长和潜在的长期并发症。高压氧治疗(HBOT)以其抗炎和抗氧化作用而闻名,已在多种疾病中显示出治疗潜力。这项前瞻性随机对照实验动物试验旨在评估HBOT对大鼠BLI模型的影响。我们采用自由落体重量法建立了BLI大鼠模型。损伤后,一组不接受干预,另一组接受HBOT治疗(2.5 ATA,每次治疗60分钟,每天一次)。在多个时间点收集肝组织和血清样本,进行组织学评估(HE染色)、细胞凋亡检测(TUNEL染色)、增殖评估(Ki67免疫组化染色),并测量肝转氨酶(ALT、AST)、炎症标志物(IL-1β、IL-6、TNF-α)和氧化应激指标(SOD、MDA、GSH)。结果表明,HBOT显著降低了肝转氨酶升高、病理损伤和肝细胞凋亡,同时促进了肝细胞增殖并加速了肝功能恢复。从机制上讲,HBOT减轻了氧化应激和炎症反应,突出了其治疗潜力。这些发现为HBOT在BLI临床治疗中的应用提供了进一步的证据。本研究通过将重点从症状管理转向基于机制的治疗,有助于推进BLI的临床治疗方法。